Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities

Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression. ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth. This therapeutic strategy, particularly using the a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-04, Vol.13 (7), p.1950-1954
Main Authors: MASSARWEH, Suleiman, SCHIFF, Rachel
Format: Article
Language:English
Subjects:
Animals
Antineoplastic agents
Antineoplastic Agents, Hormonal - metabolism
Antineoplastic Agents, Hormonal - pharmacology
Biological and medical sciences
breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Drug Resistance, Neoplasm - physiology
EGFR/HER2
endocrine therapy resistance
estrogen receptor
Female
Gynecology. Andrology. Obstetrics
Humans
Intercellular Signaling Peptides and Proteins - metabolism
Mammary gland diseases
Medical sciences
Pharmacology. Drug treatments
Receptor Cross-Talk - physiology
Receptors, Estrogen - drug effects
Receptors, Estrogen - metabolism
Signal Transduction - physiology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression. ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth. This therapeutic strategy, particularly using the antiestrogen tamoxifen, is proven to increase the cure rates in early breast cancer, improve patient outcomes in advanced disease, and reduce breast cancer incidence in the prevention setting. Despite the recent integration of more powerful endocrine agents into breast cancer care, resistance to all forms of endocrine therapy remains a major problem. New insight into ER biology and progress in understanding resistance mechanisms, mediated by molecular crosstalk between ER and various growth factor signaling pathways, are generating tremendous promise for new therapeutic opportunities to target resistance and improve breast cancer disease outcomes.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-06-2540